As a Free StocksGuide user, you can view scores for all 7,020 stocks worldwide.
8 Analysts have issued a Scilex forecast:
8 Analysts have issued a Scilex forecast:
Dec '23 |
+/-
%
|
||
Revenue | 47 47 |
292%
292%
|
|
Gross Profit | 31 31 |
319%
319%
|
|
EBITDA | -101 -101 |
380%
380%
|
EBIT (Operating Income) EBIT | -105 -105 |
376%
376%
|
Net Profit | -167 -167 |
867%
867%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.
Head office | United States |
CEO | Jaisim Shah |
Employees | 31 |
Founded | 2020 |
Website | www.scilexholding.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.